Should clinical trials prove positive, Humanigen envisions applying for a BLA, and based on the strength of its data obtaining emergency use authorization (EUA) for lenzilumab, followed by a launch of initial commercial activities as soon as the fourth quarter . . .
A ‘Human’ Touch vs. COVID-19
Tarnished in the downfall of ex-CEO Martin Shkreli, Humanigen regains its luster by targeting severe SARS-CoV-2 through its engineered monoclonal antibody
[NIAID/NIH]